Quantcast

Moderna’s director Dr. Moncef Slaoui to oversee the White House’s operation Warp Speed initiative

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Moncef Slaoui has resigned from Moderna’s Board of Directors upon appointment of his new role to oversee the White House’s Operation Warp Speed initiative.

Dr. Slaoui joined Moderna’s Board of Directors in 2017.

In the meantime Moderna said in another press release (read more here) that its vaccine candidate against novel coronavirus (SARS-CoV-2), of mRNA-1273, from the Phase 1 study showed positive interim Phase 1 data and the positive data in the mouse challenge model. The company said it will focus on moving as fast as safely possible to start its pivotal Phase 3 study in July and, if successful, file a BLA.

I would like to thank Moncef for his critical insights and three years of service on the Moderna Board,” said Noubar Afeyan, Ph.D., Co-Founder and Chairman of Moderna, and CEO of Flagship Pioneering. “Moncef’s extensive vaccine and therapeutic development guidance were important as we continue to advance Moderna’s mRNA platform. We wish him well in this new role.”

I am honored to be asked by the Administration to take on this important responsibility,” said Moncef Slaoui, Ph.D., “My entire professional career has been focused on development of therapies and vaccines to benefit many. I was inspired by Moderna’s vision to invest in developing a new class of medicines and vaccines based on messenger RNA. I have valued my time as a Board member and wish the Company the best as it continues its mission for patients.”

I greatly appreciate Moncef’s contributions to the Moderna Board in his role of Chair of the Product Development Committee,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “His expertise and skills were invaluable as we approach advanced stages of development across our clinical programs. It has been a privilege to work with Moncef over the last three years.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.